Item request has been placed!
×
Item request cannot be made.
×
Processing Request
An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Crouse JR 3rd;Crouse JR 3rd
- Source:
Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2008 Mar; Vol. 4 (3), pp. 287-304.
- Publication Type:
Journal Article; Review
- Language:
English
- Additional Information
- Source:
Publisher: Informa Healthcare Country of Publication: England NLM ID: 101228422 Publication Model: Print Cited Medium: Print ISSN: 1742-5255 (Print) Linking ISSN: 17425255 NLM ISO Abbreviation: Expert Opin Drug Metab Toxicol Subsets: MEDLINE
- Publication Information:
Publication: London : Informa Healthcare
Original Publication: London : Ashley Publications, Ltd., c2005-
- Subject Terms:
- Abstract:
Background: The HMG Co-A reductase inhibitors (statins) are the most efficacious agents for lowering cholesterol. Statins reduce clinical cardiovascular events and are generally well tolerated.
Objective: To review the efficacy and safety of rosuvastatin, the newest and most potent of the approved statins.
Methods: A comprehensive (PubMed) search was performed to identify relevant publications up to May 2007.
Results/conclusions: Rosuvastatin reduces LDL cholesterol (LDL-C) by up to 50%, and by 70% when combined with ezetimibe. Rosuvastatin also reduces plasma triglycerides and increases HDL-C, and slows atherosclerosis progression in coronary and carotid arteries in both low-risk and high-risk individuals. Tolerability is comparable with other statins. Clinical trials to evaluate cardiovascular outcomes have recently been published (CORONA) or are underway.
- Number of References:
143
- Accession Number:
0 (Cholesterol, LDL)
0 (Fluorobenzenes)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
0 (Liver-Specific Organic Anion Transporter 1)
0 (Pyrimidines)
0 (Sulfonamides)
83MVU38M7Q (Rosuvastatin Calcium)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
EC 1.14.14.55 (CYP3A4 protein, human)
- Publication Date:
Date Created: 20080328 Date Completed: 20080812 Latest Revision: 20220408
- Publication Date:
20240829
- Accession Number:
10.1517/17425255.4.3.287
- Accession Number:
18363544
No Comments.